The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
Open Access
- 1 March 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 97 (5), 1413-1421
- https://doi.org/10.1182/blood.v97.5.1413
Abstract
SU5416 and SU6668 are potent antiangiogenic small-molecule inhibitors of receptor tyrosine kinases, including those of the vascular endothelial growth factor and platelet-derived growth factor receptor families. The stem cell factor (SCF) receptor, c-kit, is structurally related to these receptors and, although not expressed on mature peripheral blood cells, is expressed in leukemic blasts derived from 60% to 80% of acute myeloid leukemia (AML) patients. The c-kit kinase inhibitory activity of SU5416 and SU6668 was evaluated in MO7E cells, a human myeloid leukemia cell line. Tyrosine autophosphorylation of the receptor, induced by SCF, was inhibited in these cells by SU5416 and SU6668 in a dose-dependent manner (inhibitory concentration of 50% [IC50] 0.1-1 μM). Inhibition of extracellular signal–regulated kinase 1/2 (ERK1/2) phosphorylation, a signaling event downstream of c-kit activation, was also inhibited in a dose-dependent manner. Both compounds also inhibited SCF-induced proliferation of MO7E cells (IC50 0.1 μM for SU5416; 0.29 μM for SU6668). Furthermore, both SU5416 and SU6668 induced apoptosis in a dose- and time-dependent manner as measured by the increase in activated caspase-3 and the enhanced cleavage of its substrate poly(ADP-ribose) polymerase. These findings with MO7E cells were extended to leukemic blasts from c-kit+ patients. In patient blasts, both SU5416 and SU6668 inhibited SCF-induced phosphorylation of c-kit and ERK1/2 and induced apoptosis. These studies indicate that SU5416 and SU6668 inhibit biologic functions of c-kit in addition to exhibiting antiangiogenic properties and suggest that the combination of these activities may provide a novel therapeutic approach for the treatment of AML.Keywords
This publication has 17 references indexed in Scilit:
- Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migrationJCI Insight, 2000
- Evidence of increased angiogenesis in patients with acute myeloid leukemiaBlood, 2000
- Cellular Vascular Endothelial Growth Factor Is a Predictor of Outcome in Patients With Acute Myeloid LeukemiaBlood, 1999
- Inhibition of Tumor Growth, Angiogenesis, and Microcirculation by the Novel Flk-1 Inhibitor SU5416 as Assessed by Intravital Multi-fluorescence VideomicroscopyNeoplasia, 1999
- The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated LeukemiasBlood, 1998
- Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factorBlood, 1992
- Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cellsBlood, 1991
- Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptorCell, 1990
- The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogeneCell, 1988
- The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locusNature, 1988